## **Core Concept**
Ipilimumab is a type of immunotherapy drug used in the treatment of certain cancers, most notably metastatic melanoma. It works by targeting and inhibiting a specific protein that plays a crucial role in regulating the immune response. This class of drugs is known as checkpoint inhibitors.

## **Why the Correct Answer is Right**
Ipilimumab specifically targets the **CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4)**, a protein receptor that downregulates the immune system by binding to B7 molecules on antigen-presenting cells. By inhibiting CTLA-4, ipilimumab enhances the immune response against cancer cells, allowing the immune system to recognize and attack these cells more effectively.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because ipilimumab does not primarily target PD-1 (Programmed Death-1), which is another checkpoint protein but distinct from CTLA-4. Drugs targeting PD-1 include nivolumab and pembrolizumab.
- **Option B:** This option is incorrect as ipilimumab is not classified as a chemotherapeutic agent, which typically works by directly killing rapidly dividing cells, such as cancer cells.
- **Option C:** This option is incorrect because ipilimumab does not target LAK (Lymphokine-Activated Killer) cells directly. LAK cells are involved in cellular immunotherapy but are not the direct target of ipilimumab.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl to remember is that ipilimumab can cause significant immune-related adverse effects (irAEs), such as dermatitis, colitis, and hepatitis, due to its mechanism of enhancing the immune response. Early recognition and management of these side effects are crucial for safe treatment.

## **Correct Answer:** D. CTLA-4 inhibitor.